Vanguard Fiduciary Trust
CGEM icon

Vanguard Fiduciary Trust’s Cullinan Oncology CGEM Stock Holding History

Vanguard Fiduciary Trust’s Portfolio CGEM Stock Details CGEM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.61M Buy
363,136
+20,284
+6% +$301K ﹤0.01% 2033
2026
Q1 		$4.87M Buy
+342,852
New +$4.41M ﹤0.01% 2091

Other funds holding CGEM

MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

Vanguard Fiduciary Trust's CGEM Position: Q2 2026 in Review

Vanguard Fiduciary Trust increased its Cullinan Oncology (CGEM) stake by 5.9% in Q2 2026, buying an estimated $301K and bringing the position to 363,136 shares worth $6.61M. The position accounts for ﹤0.01% of the portfolio, ranked #2033.

Vanguard Fiduciary Trust first reported a position in CGEM in Q1 2026 and has held it in 2 quarters since. 182 funds tracked by Wall St. Rank hold CGEM as of Q2 2026.

  • Vanguard Fiduciary Trust held 363,136 shares of Cullinan Oncology worth $6.61M as of Q2 2026.
  • Vanguard Fiduciary Trust bought 20,284 Cullinan Oncology shares in Q2 2026, an estimated $301K.
  • Cullinan Oncology made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #2033 holding.
  • Vanguard Fiduciary Trust first reported a position in Cullinan Oncology in Q1 2026 and has held it in 2 quarters since.
  • 182 funds tracked by Wall St. Rank held Cullinan Oncology as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.